• Publications
  • Influence
PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence.
The proto-oncogene pituitary tumor-transforming gene (PTTG) is described as abundantly overexpressed in a variety of neoplasms and cancer cell lines. We analyzed PTTG mRNA expression in 72 tumorExpand
  • 116
  • 5
Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts.
The antitumor activity of ecteinascidin (ET)-743, a novel marine natural product, was evaluated against a panel of human ovarian carcinoma xenografts characterized by different malignant behaviorsExpand
  • 126
  • 2
  • PDF
Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells.
The effect of paclitaxel on the adhesive and motility properties of human ovarian carcinoma cell lines was investigated. Paclitaxel significantly inhibited the motility of OVCAR 5, SK-OV-3, andExpand
  • 64
  • 2
A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
We have identified a soluble form of the human urokinase plasminogen activator (uPA) receptor (uPAR) in the ascitic fluids from patients with ovarian cancer. After purification of uPAR from theExpand
  • 121
  • 1
  • PDF
Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
Batimastat (also known as BB-94) is a synthetic matrix metalloproteinase inhibitor that has shown antineoplastic and antiangiogenic activity in various tumor models. In this study, two human ovarianExpand
  • 88
  • 1
  • PDF
IDN5109, a taxane with oral bioavailability and potent antitumor activity.
IDN5109 is a new taxane, derived from 14beta-hydroxy-10-deacetylbaccatin III, selected for its lack of cross-resistance in tumor cell lines expressing the multidrug resistant phenotype. Because,Expand
  • 71
  • 1
  • PDF
Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts.
We have investigated gene expression profiles of human ovarian carcinomas in vivo during Taxol(R) (paclitaxel) treatment and observed a difference in expression. Nude mice bearing 1A9 or 1A9PTX22Expand
  • 73
  • 1
Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
PURPOSE We previously reported that paclitaxel, a microtubule-stabilizing drug, inhibited angiogenesis, mainly by inhibiting endothelial cell motility (D. Belotti et al., Clin. Cancer Res., 2:Expand
  • 60
  • 1
  • PDF
Pituitary tumor-transforming gene (PTTG): a novel target for anti-tumor therapy.
BACKGROUND The proto-oncogene pituitary tumor-transforming gene (PTTG) is described as abundantly over-expressed in a variety of neoplasms with impact on neovascularization and tumor invasiveness.Expand
  • 32
  • 1
Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice.
BACKGROUND The unique mechanism of action of taxol (NSC-125973) as microtubule stabilizing agent and its potential activity in clinical trials have generated considerable interest in the developmentExpand
  • 30
  • 1
...
1
2
3
...